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To analyze prospectively the interventional and clinical aspects of computed tomography-guided direct intratumoural injection
of a novel chemotherapeutic administration and the parenchymal changes of tumour and necrosis in malignant liver tumours.
Eight patients with 17 colorectal liver metastases were treated with a mean of 5.1 injections and nine patients with 13
hepatocellular carcinoma nodules with a mean of 3.1 treatments with computed tomography guided local applications of a
novel cisplatin/epinephrine gel. This application provides a higher local and lower systemic drug concentration. Volumes of
tumour and necrosis prior and after treatment were measured by computer generated volumetric analysis. Contrast enhanced
studies veriﬁed pretherapeutic viable tumour volumes with a value of 77.4 ml in the metastases and 29.2 ml in the
hepatocellular carcinoma nodules. Intratumoural drug application resulted in a signiﬁcant increase of necrosis and a decrease in
viable tumour volume to be 68.3 ml in metastases and 14.5 ml in hepatocellular carcinoma. Local therapy control rate for the
follow up to 6 months was 38 and 71% for the group of metastases and hepatocellular carcinoma, respectively. Direct
intratumoural injection of cisplatin/epinepthrine injectable gel is a feasible and good tolerated method and results in the
development of a statistically signiﬁcant increase in necrosis in malignant liver tumours. For hepatocellular carcinoma a higher
local therapy control rate compared to colorectal metastases can be reported.
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Primary and secondary liver malignancies are the most frequent
cause of death in oncologic patients, the only potential curative
treatment is surgical resection. In patients with colorectal liver
metastases, only 10 to 30% are considered for a resection
(August et al, 1985; Schlag et al, 1991); in patients with an
isolated liver involvement, 20 to 40% (Lorenz et al, 1997). If
resection is not possible, then improved quality of life through
maximal control of liver lesions must be the goal. Treatment
options include systemic or regional chemotherapy, transarterial
chemoembolization, percutaneous ethanol injections, laser-
induced interstitial thermotherapy, cryotherapy and radio-
frequency ablation.
As a palliative treatment with lower side effects regional
chemotherapy seems to provide higher local drug concentrations,
higher response rates, and less systemic toxicity compared to
systemic application (Collins, 1984; Rougier et al, 1992; Venook,
1997). Direct intratumoural percutaneous injections deliver even
higher drug concentrations to selective sites, are minimally inva-
sive, and effectively produce necrosis (Curley et al, 1995). A
novel injectable gel has been developed containing cisplatin as
the chemotherapeutic and epinephrine as the vasoconstricting
agent. This allows high drug concentrations to the treatment site
and a slow dispersion to the surrounding tissues, thus reducing
systemic exposure. In preclinical studies, conventional chemother-
apeutic agents such as cisplatin, ﬂuorouracil, or vinblastine
administered intratumourally in the gel formulation enhanced drug
retention and increased antitumoural efﬁcacy (Curley et al, 1995).
Injectable gels have been used to treat various spontaneous
tumours in veterinary patients and human malignancies such as
basal and squamous cell carcinomas and accessible solid tumours
of various histologic types (Miller et al, 1997; Burris et al, 1998).
A recent french study showed development of therapy-induced
necrosis after percutaneous intratumoural injections of mitoxan-
trone in primary and secondary liver malignancies (Farre ￿s et al,
1998).
MATERIALS AND METHODS
This study is part of a multicentre, open-label, phase II trial on the
safety and efﬁcacy of percutaneous intratumoural administration of
Cisplatin/epinephrine (CDDP/epi) injectable gel in patients with
hepatic metastases of colorectal cancer and patients with unresect-
able primary hepatocellular carcinoma. The investigational agent,
CDDP/epi gel (IntraDose
1 Injectable Gel, Matrix Pharmaceutical,
Inc., Fremont, CA, USA) is an injectable, biodegradable, viscous
gel composed of cisplatin (CDDP, 4 mg ml
71); the vasoconstric-
tor, epinephrine (epi, 0.1 mg ml
71 to a maximum of 1 mg per
injection); a protein carrier matrix (puriﬁed bovine collagen,
2m gm l
71) as a gellant; and other inactive excipients as buffering
and osmotic agents. The components are mixed within 2 h of use.
The IntraDose
1 gel has a gelatinous consistency at room tempera-
ture and can ﬂow through a 19.5-gauge needle for direct
percutaneous injection in the liver tumour.
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Seventeen patients were included, nine patients with unresectable
hepatocellular carcinoma (HCC) and eight patients with unresect-
able colorectal liver metastases (CRLM). Seventeen CRLM in eight
patients were treated with an average of 5.1 injections per patient
(range 1–8) and in nine patients with HCC 13 lesions were treated
with an average of 3.1 injections (range 1–4). The number of
injections depended on parameters such as tumour size and general
condition of the patient. The average patient age was 67.1 years
(range 39–79 years), 13 patients were male, four female. All
patients had previously undergone other oncologic treatments
before entering the study. One patient with HCC had prior
chemoembolization for seperate lesion, all patients with colorectal
metastases had received systemic chemotherapy with 5-Fluorouracil
and folinic acid and three patients had undergone liver resection.
All patients had either progressive or recurrent disease after
previous treatment.
The study is open to adult patients with up to three intrahepatic
biopsy proven tumours (HCC or metastases of colorectal carcino-
ma) with no extrahepatic spread, Karnofsky Performance Status
should be 40 or more and the laboratory results have to be within
ranges deﬁned by protocol. Coronary artery disease, history of
gastro-oesophageal varices, encephalopathy or bleeding from liver
tumours as well as known hypersensitivity to one of the ingredients
of the gel or radiographic contrast agents were exclusion criteria.
Patients signed a written informed consent proven by the local
ethics committee.
Study design
Prior to treatment patients had a complete history, physical exam-
ination, laboratory studies and helical contrast-enhanced computed
tomography (CT) scans. Treatment consisted of up to 4 weekly
percutaneous intratumoural administrations of IntraDose
1 gel
with up to 10 ml gel (=40 mg Cisplatin) at each treatment session.
A second cycle of four treatments could follow the ﬁrst at the
discretion of the investigator. Contrast-enhanced helical CT scans
were performed at 2 weeks, 2 months and 6 months after each
treatment cycle. After 6 months patients were followed at 3 month
intervals by visits or telephone calls.
Injection technique
Before each treatment, patients are hydrated with intravenous infu-
sions of 500–1000 ml of saline, 0.9% sodium chloride solution.
After a plain CT scan the intrahepatic administration of Intra-
Dose
1 gel was performed under local anaesthesia. To allow a
safe lesion localization and homogeneous distribution of the gel
throughout the whole tumour volume, several localizations of the
needle tip are required in most cases. For this a computer-gener-
ated guidance system (CARE
1 Vision CT, Siemens, Erlangen,
Germany) which made nearly online visualization possible was
used (see Figure 1) (Froelich et al, 1997). A 19.5-gauge stainless
steel puncture needle with six side holes at the tip to support
the distribution of the gel was utilized (SOMATEX
1, Berlin,
Germany). Blood pressure and heart rate were monitored during
the treatment procedure. Afterwards the patient had 6 h bed rest.
Imaging procedures
Hepatic lesions were evaluated via unenhanced and contrast-
enhanced CT studies performed with a helical CT scanner (SOMA-
TOM Plus 4
1, Siemens AG, Erlangen, Germany). Continuous 5-
mm-slice acquisition was used. After the unenhanced CT images
were obtained, 120 ml of a non-ionic contrast agent (Ultravist
370
1, Schering AG, Berlin, Germany) was administered. The
contrast-enhanced helical CT scans were obtained in three phases
with the indicated volume, ﬂow, and time delay parameters: arter-
ial phase (volume, 120 ml; ﬂow, 2.5 ml s
71; time delay, 20 s);
portal venous phase (120 ml, 2.5 ml s
71, 70 s); and venous equili-
brium phase (120 ml, 2.5 ml s
71, 300 s). Image reconstruction
parameters included 5-mm slice thickness; 7.5 mm per second
feed/rotation, and 5 mm increment.
Quantitative analysis
Quantitative analyses were performed using the region-of-interest
(ROI) technique to determine viable tumour volume and volume
of tumour necrosis in the CT scans. The tumour/necrosis areas
were marked manually on each CT slice at the CT console, then
the volumes were calculated using also the slice thickness. This is
one of the most accurate means to determine volumes in CT.
Tissues enhanced with contrast media were assumed to be viable
and unenhanced tissue nonviable or necrotic. Tumour size, viable
tumour volume, and tumour necrosis were assessed before treat-
ment, 2 weeks, 2 and 6 months after treatment then at 3-month
intervals.
RESULTS
Pretherapeutic initial volumetric CT imaging revealed a mean
tumour volume per patient of 91.3 ml in colorectal metastases
(range 2–125 ml, median 107 ml) and 31.4 ml in HCC (range
1–113 ml, median 16 ml). Measurements of pretherapeutic
tumour necrosis in the contrast enhanced studies resulted in a
mean value of 13.9 ml for the group of metastases and in 0.4 ml
for the group of HCC, the measurements of viable tumour resulted
in 77.4 ml for the metastases and 29.2 ml for HCC. After intra-
tumoural drug application quantitative CT evaluation revealed an
increase of necrosis in contrast to the initial studies in all patients.
Mean necrotic volume 2 weeks after the ﬁnal treatment resulted in
a decrease in viable tumour revealed to be 68.3 ml for metastases
(tumour/necrosis volume: 176.4/108.1 ml) and 14.5 ml for HCC
(tumour/necrosis volume: 41.8/27.3 ml). However viable tumour
at Month 2 control showed a progression again especially for the
CRLM to mean 103 ml (tumour/necrosis volume: 219/116 ml)
and for the HCC to 21.6 ml (tumour/necrosis volume: 42/
20.4 ml) (see Figure 2). Statistical calculations using the Student
t-test did show that the increase of necrosis after therapy for the
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Figure 1 Visualization of the injection procedure in a hepatic metastasis
(open arrows) shown in segment 5 using the CARE vision CT programme.
Note the needle placed centrally in the tumour (arrow).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 524–529HCC is statistically signiﬁcant (P=0.001/0.003 after 2 weeks/2
months with a 95% conﬁdence interval), the change of tumour
volume is not signiﬁcant (P=0.65). Although vital tumour in
HCC decreased from 29.2 to 14.5 ml this change is not statistically
signiﬁcant (P=0.3). In the group of CRLM a signiﬁcant increase in
necrosis (P=0.001/0.002 after 2 week/2 months) but also in tumour
volume (P=0.05) was found. Also as in HCC the decrease in vital
tumour was not signiﬁcant (P=0.44 after 2 months).
Evaluable for efﬁcacy were seven patients with colorectal metas-
tases and eight patients with HCC. One patient with colorectal
metastasis withdrew from treatment after the ﬁrst injection, in
one patient with HCC and progressive liver cirrhosis treatment
was discontinued after one injection due to worsening laboratory
values.
The CT scans revealed a variety of tissue changes in the periph-
eral area of the tumour/necrosis. In colorectal metastases, the
hypodense areas were larger in comparison to the initial tumour
volume and showed an inhomogeneous contrast enhancement
and poorly deﬁned margins. The HCC nodules generally developed
a more sharply deﬁned necrosis and no contrast enhancement in
the peripheral areas. If the follow up control scans did not show
signs of remaining tumour activity, these changes were attributed
to oedema and peritumoral reactions. In addition, remaining
vessels with a relevant perfusion rate could be detected next to
the treated region in the arterial phase of the CT scan.
The CT-Fluoroscopy supported an easy and safe performance
of the injections. Complications due to intravascular or intrabili-
ary injections, signiﬁcant bleeding or a pneumothorax were not
observed. The modiﬁed treatment needle permitted adequate
distribution of the gel within the tumour, although a better visua-
lization of the gel would be desirable. Small tumours with a
volume of a few ml could be reached without complications.
For example, a HCC nodule of initially 3 ml showed complete
necrosis after four injections without signs of tumour viability
both in the 6 month follow-up CT scan and later studies. In
the Figures 3a–c and 4a,b, examples of treated tumours are
shown.
Clinical follow up
In the patients with liver metastases, CT-evaluation revealed local
tumour control in only three patients with a total of four lesions
(local tumour control rate 26%). In six patients (75%), new
intrahepatic tumours were detected. Local tumour control was
deﬁned as complete inactivity of the treated lesions in the 3
and 6 month follow-up scans. Of the eight patients in the
HCC group local tumour control rate was 70%. Three patients
developed new HCC manifestations (43%). Two patients with
worsening liver function and interrupted treatment were not
included in the evaluation for local tumour control rate. At this
time all eight patients with colorectal metastases and seven of the
nine HCC patients died as a result of their disease. During the
period for the determination of the control rates only one
patient with HCC received another anti-tumour therapy
(chemoembolization), no systemic chemotherapy was adminis-
tered.
The survival rates were calculated with the Kaplan–Meier meth-
od. The overall cumulative survival for all 17 patients included was
13.15 months (median 10.17 months; mean 95% Conﬁdence inter-
val 9.25–17.06 months). The survival of the eight patients with
CRM was 14.48 months of the nine patients with HCC, 14.11
months. This data can only show a tendency since the number
of patients is very small.
Clinical effects: tolerance, side effects
Overall the treatment procedure was well tolerated. During and
immediately after injection the patients suffered from transient
local pain (76%), an increase in blood pressure, and heart palpi-
tations during injection (24%) and sweating or shoulder pain
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Figure 2 Volumetric measurements of viable tumour volumes before
treatment (screen) and 2 weeks and 2 months after last treatment.
a
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Figure 3 (a) 69-year-old patient with histopathologically proven HCC in
segment 5/8. Pretreatment CT scan on the left side, lesion identiﬁed with
decreased attenuation values. CT scan 2 weeks after the fourth/last treat-
ment with IntraDose
1 gel. Segment 5/8 reveals an irregular area of necro-
sis that developed after treatment (arrows). Both scans portal venous
phase. (b) MRI scan (T2-weighted) 2 years after treatment, The lesion is
still detectable but has not changed in size, the patient is in a good clinical
condition.
Local treatment of liver malignancies
TJ Vogl et al
526
British Journal of Cancer (2002) 86(4), 524–529 ã 2002 Cancer Research UK(each 30%). Nausea and vomiting were initially seen in 53%, but
could be reduced with pretherapeutic infusion of cortisone
(Merck, Darmstadt, Germany) and ondansetron (Glaxo Well-
come, Bad Oldesloe, Germany). Clinical signs of cisplatin-
induced toxicity like nephrotoxicity, peripheral neurotoxicity or
ototoxicity did not occur. Laboratory results were obtained
before every treatment and evaluation and did not show major
toxicity (for toxicity see Table 1). Transient elevation of alkaline
phosphatase, transaminases and a slight decrease in haemoglobin
and lymphocytes could be detected in some patients but never
with therapeutic consequences. One patient with hepatitis
induced Child-Pugh B classiﬁed liver cirrhosis (total bilirubin
initially 3.4 mg dl
71) died due to liver failure (increasing biliru-
bin results 10 days after the ﬁrst treatment). Another patient
with Child-Pugh B classiﬁed liver cirrhosis (total bilirubin initi-
ally 4.1 mg dl
71) showed increasing bilirubin values resulting
in termination of treatment. Therefore a connection between
the worsening liver function and treatment must be considered.
The death was assessed as a serious adverse event.
DISCUSSION
In order to increase the therapeutic index of the drugs, regional
treatments for primary and secondary liver tumours are in use.
Regional drug infusion parameters, like the hepatic extraction
and the regional blood ﬂow, are inﬂuencing the pharmacokinetic
properties. The collagen matrix gel mixed with cisplatin and
epinephrine alters both these factors. It maintains the cisplatin at
high concentrations in the treated tumour and so induces an
increased cellular extraction of the drug. Further, it reduces the
blood ﬂow in the region of the tumour by three factors: the vaso-
constriction caused by the epinephrine which is added to the
collagen and the cisplatin, the compression of the tumour vessels
by the increasing intratumoural pressure following injection and
by occlusion of tumour vessels by collagen matrix gel inﬁltrating
into tumour vascular spaces (Davidson et al, 1995).
Preclinical studies indicated that via the local application of the
IntraDose
1 gel 20 to 30 times and higher intratumoural cytostatic
concentrations can be achieved compared to systemic application.
The antitumourous effect is thought to be due to the combina-
tion of substances as epinephrine gel alone did show rapid tumour
recurrence in veterinary trials, and addition of epinephrine to the
Cisplatin gel showed an improvement of the effect.
Additionally pretherapeutical hydratation of the patient is
expected to further reduce systemic toxicity (Hayes et al, 1977).
Curley et al (1995) are reporting on the induction of a signiﬁcant
tumour necrosis and reduction in tumour volume in lesions as
large as 12 cm in diameter in human liver malignancies. No cispla-
tin-related toxicity was reported, the treatments were well tolerated
with a transient pain at the injection site and in the liver from
stretching the liver capsule (Curley et al, 1995). These published
data are offering the basis for our in vivo studies.
The effects of percutaneous intratumoural administration of
Intradose
1 gel have to be compared with systemic chemotherapy
and other local treatments such as local ethanol instillation,
chemoembolization and arterial chemo perfusion as well as to no
treatment.
The comparative analysis of our data shows that CT-guided intra-
tumoural injection of CDDP/epi gel has induced a statistic
signiﬁcant increase in necrosis in both groups. However, the local
effectiveness based on the rate of local recurrences was higher in
patients with HCC vs the patients with metastases, in HCC local
tumour control was 70% and in CRLM only 26%. The response in
CRLM is comparable with these after systemic chemotherapy which
mainly remains below 30% (Kemeny et al, 1993). For the HCC our
results are comparable to these after chemoembolization or hepatic
arterial infusion, a response of 30–60% after TACE (Takayasu et
al, 1989; GTCH 1995; Colella et al, 1998) and 40–50% after HAI
(Carr, 1996; Patt et al, 1997) is reported. Here complications due
to hepatobiliary toxicity may occur, especially in cirrhotic patients
when the liver function is reduced (Ravoet et al, 1993; Kemeny,
1995). However complete necrosis of 80–90% can be reached with
percutaneous ethanol injection in small HCC (Livraghi et al, 1999).
An efﬁcient and innovative treatment for malignant liver tumours
– metastases and HCC – in patients with unresectable lesions is MR-
guided laser-induced thermotherapy (LITT). This minimally inva-
sive, locoregional technique results in a reliable local tumour
control rate of more than 95% in lesions 440 mm in diameter (Vogl
et al, 1998). Similar to LITT percutaneous radiofrequency (RF) abla-
tion is another ablative method used to induce thermal coagulation
of tumour tissue. Both are competitive methods to surgical resection
and should not be responded to in detail in this work.
The different results in both groups might be due on the one
hand to the different morphology and growth pattern in the
HCC nodules. These tumours are regularly encapsulated and have
a lower degree of peritumoural spread; thus, the intratumoural
pressure after injection may be higher in HCC and may result in
a more homogeneous distribution of the drug. On the other hand
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Figure 4 A 55-year-old patient with colorectal metastases to the liver.
(a) Pretreatment CT scan in segment 8 (portal venous phase). (b) CT scan
(portal venous phase) at 8 weeks after the pretreatment evaluation and 2
weeks after the fourth treatment. Increased tumour necrosis is evident after
treatment.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 524–529the group of patients with CRLM had a more palliative character
reﬂected in the high number of patients that developed new intra-
hepatic metastases.
The survival data has to be judged carefully since the number of
patients is relatively low in our study. But an advantage in survival
can be seen to emerge in contrast to no treatment, in the CRLM
mean survival with 14.6 months is higher than the 7.5 months
reported by Stangl et al (1994) in a large German study on patients
with CRLM receiving no treatment. The survival in HCC is
approximately similar than with only palliative treament (Okuda
et al, 1985).
Further trials are continuing to assess the inﬂuence of Intra-
Dose
1 gel on increased survival of patients with non-resectable
liver cancers. A second objective is to establish the optimum
tumour size criteria for treatable lesions. Also randomized and
combined trials with systemic chemotherapy or chemoembolization
are planned.
Conclusion
In summary, direct intratumoural injection of CDDP/epi
injectable gel is a feasible and well tolerated method with-
out major toxicity and results in the development of a
relevant necrosis in malignant liver tumours. For HCC, a
higher local therapy control rate compared to colorectal
metastases was seen.
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Table 1 Toxicity criteria (NCCOG/NCI) (North Central Cooperative Oncology Group/
National Cancer Institute, 1991)
Toxicity 0 1 2 3 4
Blood/bone marrow
Haemoglobin Colorectal 6 1 1 0 0
HCC 8 1 0 0 0
Lymphocytes Colorectal 7 1 0 0 0
HCC 5 2 2 0 0
White blood cells Colorectal 8 0 0 0 0
HCC 9 0 0 0 0
Coagulation proﬁle
Partial thromboplastin time Colorectal 8 0 0 0 0
HCC 9 0 0 0 0
Prothrombin time Colorectal 8 0 0 0 0
HCC 6 3 0 0 0
Creatinine Colorectal 8 0 0 0 0
HCC 8 1 0 0 0
Hypocalcaemia Colorectal 6 2 0 0 0
HCC 7 2 0 0 0
Liver
Alk. phosphatase Colorectal 5 2 1 0 0
HCC 2 4 2 0 1
Bilirubin Colorectal 8 0 0 0 0
HCC 4 0 0 3 2
Transaminases Colorectal 8 0 0 0 0
HCC 5 3 1 0 0
Liver, clinically Colorectal 8 0 0 0 0
HCC 7 0 0 1 1
Gastrointestinal
Nausea Colorectal 6 (3)
a 2 (5)
a 000
HCC 8 (5) 1 (4) 0 0 0
Vomiting Colorectal 7 (6)
a 1 (2)
a 000
HCC 8 (7)
a 1 (2)
a 000
Other
Anorexia Colorectal 6 2 0 0 0
HCC 7 2 0 0 0
Anergy Colorectal 6 1 1 0 0
HCC 7 2 0 0 0
Shoulder pain Colorectal 5 1 2 0 0
HCC 7 2 0 0 0
Cardiac symptoms Colorectal 5 2 0 1 0
HCC 8 1 0 0 0
Neurocortical symptoms Colorectal 8 0 0 0 0
HCC 8 1 0 0 0
aNumbers in brackets refer to symptoms during injection.
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